Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

189.26 -2.14 (-1.12%)
Official Closing Price Updated: 6:30 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
Via The Motley Fool
Elliott Wave Technical Analysis: AbbVie Inc. - Wednesday, March 19
A pullback in Wave {iv} is expected before resuming the overall trend. 
Via Talk Markets
Topics Stocks / Equities
3 Dividend Stocks to Buy for Reliable Passive Income
Via The Motley Fool
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
13 Analysts Have This To Say About AbbVie
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients
AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data. 
Via Benzinga
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction
Via The Motley Fool
Topics ETFs
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
Via Investor's Business Daily
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Vanguard has some excellent dividend ETFs, but they are right for different investors. 
Via The Motley Fool
Topics ETFs
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors. 
Via The Motley Fool
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
Via The Motley Fool
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among... 
Via Stocktwits
3 Stocks Breaking Out Right Now
These three stocks are touching new all-time highs. 
Via Talk Markets
Topics Stocks / Equities
Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today?
Via The Motley Fool
Topics ETFs Stocks
3 Cheap Stocks to Buy With Your Tax Refund Check
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
Via Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.